The observed improvement in platelet response among patients with ITP treated with SYK and BTK inhibitors can be attributed to their targeted interference with key immune signaling pathways involved in the pathogenesis of the disease.4,7. The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.